Price Watch

Center for Medicare Stalls on its Decision to Cover CAR-T

Modern Healthcare reports the Center for Medicare (CMS) recently postponed its decision on whether to cover the pricey breakthrough cancer treatment known as CART-T...

$2.1 M Gene Therapy for SMA Approved by FDA

Novartis’ (Avexis) received FDA approval for Zolgensma, the first and only therapy for pediatric patients with spinal muscular atrophy (SMA). The therapy will be...
Price Fixing

Generic Drug Price Fixing: 44 States Sue Generics Over Multi-Year Conspiracy to Hike Prices...

TrialSite News reports that state attorneys general of more than 40 states filed a lawsuit accusing the nation’s largest generic drug makers of conspiring...

Clinical Research as Care: Cut the Patient off Post Clinical Trial—A Lose-Lose in the...

Deborah Cohen of the BBC reports that patients in the UK who contributed to orphan studies only to be cut from ongoing access once...
Kidney Cancer

The Second Xiangya Hospital & Team Study Reveals Yervoy & Opdivo Cost-Effective Kidney Cancer...

The Second Xiangya Hospital and team demonstrated the combination use of Yervoy (ipilimumab) plus Opdivo (nivolumab) was estimated to be cost-effective compared with Sutent...

PriceWatch: Is the High Cost of Insulin Keeping Patients from Taking Meds?

Kaiser Health News recently reported that drug price escalations have become a nationwide topic. Democratic Presidential Candidate Sen. Kamala Harris of California noted at...
Drug Pricing

PriceWatch: Florida Republican Governor Backing Sanders Drug Pricing Control Plan

Michael Graham, editor of InsideSources reports that Florida Gov. Ron DeSantis is pushing a state-level drug reimportation bill like the one passed by the...
cancer research

Greek Investigator Seeks to Make CAR-T Far Cheaper than Novartis & Kite Pharma!

  NeoCosmos reports a Greek assistant professor of medicine at the VUmc Cancer Centre in Amsterdam, Dr. Maria Themeli, is determined to make her patent...

Tech Transfer & Drug Prices: The Best of Times and the Worst of Times

These are the best and worst of times in all facets of life, including drug development. Breakthrough treatments can extend survival by many years—what...
Drug Pricing

ICER’s Growing Impact on Drug Pricing & Reimbursement

Forbes reports on the growing clout of the Institute for Clinical and Economic Review (ICER).  Sometimes referred to American’s ‘NICE’ a reference to the...